SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rally to a 52-week high is driving discussion, with traders citing momentum and rotation into defensive, dividend-paying pharma amid broader market weakness. Bulls see a potential breakout, while skeptics point to resistance and say a fresh company-specific catalyst is needed.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings and revenue beat and a new multiyear buyback, as traders focus on the narrowed profit outlook with its midpoint unchanged and declining U.S. sales and market share. Some see the decline as a buying opportunity given cash generation and capital returns, while others argue the outlook failed to justify the valuation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanley named Amazon a top pick, citing accelerating AWS growth and AI opportunities, prompting a sharp rally. Traders welcomed the upgrade, while others questioned whether the move can hold and are watching resistance and the upcoming earnings report for confirmation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp selloff across AI infrastructure and neocloud stocks as investors question whether heavy data-center spending and financing risks will generate adequate returns, with Gartners warning adding to the concern. Traders disagree on whether the pressure signals more downside or an oversold opportunity, with bulls pointing to IRENs contracted demand, power assets, and managements financing reassurances.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after quarterly results beat expectations and the company raised its full-year outlook, citing strong aerospace and defense demand and a record backlog. Traders broadly praised the results, while some questioned why the share-price reaction was muted.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rebound and improving technical momentum are driving attention to IBIT, with bullish traders treating consolidation and pullbacks as opportunities to add and anticipating further gains. Others caution that the rally could fade, citing resistance and macroeconomic risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GSK Pharma India Shareholders Approve Appointment of CFO Ronojit Biswas via Postal Ballot

GlaxoSmithKline Pharmaceuticals Limited ( ($IN:GLAXO) ) just unveiled an announcement. GlaxoSmithKline Pharmaceuticals Limited has concluded a post...

GSK Pharma Slapped Rs 23.21 Crore Tax Demand, Plans Appeal

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma ) has received a tax demand of Rs 23.21 crore from the Income Tax Department following a scrutiny assessment for the Assessment Year 2023-24.

GST Blow: Maharashtra Authorities Slap Rs 6.92 Crore Tax Demand on GSK Pharma

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received a tax demand … portal and was received physically. GlaxoSmithKline Pharmaceuticals Limited stated that the tax demand …

MP GST Dept Slaps Rs 3.79 Crore Tax, Penalty Demand on GSK Pharma

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received … and documentation requirements. GlaxoSmithKline (GSK) Pharmaceuticals Limited clarified in its … appropriate action as necessary. GlaxoSmithKline Pharmaceuticals Limited, the Indian subsidiary …

GSK India plans big 'reinvention'

Mumbai: Global biopharma major GlaxoSmithKline Pharmaceuticals, best known in India for its blockbuster legacy brands Augmentin and Calpol, is charting a bold comeback in the country. The London-headquartered company, which has completed over a century in India's pharma market, is plotting its most ambitious transformation in decades as it targets doubling its India revenue to ₹8,000 crore within 4-5 years, India MD Bhushan Akshikar told ET in an exclusive interview.This will be driven by a strategic pivot from its ₹4,000-crore base of legacy portfolio of general medicines-including medications in anti-infective, pain management, respiratory and vaccines-into specialty drugs in high-growth areas of oncology and liver diseases as well as nascent areas such as adult vaccination."Reinvention and impact are the two words that define our journey in India. Taking cue from our past but remaining completely focused on the future is how I see the next decade for us," said Akshikar. "Our base business will continue to grow while on top of that we are launching in areas where we can make a sizeable impact," he added.The bet will be on innovation-led growth, accelerated clinical trials in India, and concurrent launches of global assets to double size by the end of the decade.

GSK Pharma to Procure 4.95 MWp Solar Power from CleanMax in Maharashtra

GlaxoSmithKline Pharmaceuticals (GSK Pharma ) will procure 4.95 MWp … , Syngene International, a Bengaluru-based pharmaceutical company, announced procuring renewable energy … February 2025, Mumbai-based Aarti Drugs partnered with Prozeal Green Energy …

GSK Pharma to Procure Power from CleanMax’s 4.95 MW Solar Project

GlaxoSmithKline Pharmaceuticals (GSK) has announced it will source power from a 4.95 MW solar project of Clean Max Galapagos, a special purpose vehicle (SPV) of CleanMax, in Maharashtra.

Top Diwali 2025 Picks: ICICI Bank, Varun Beverages, Finolex Among Nirmal Bang’s Favorites

Equity

From banking to beverages, Nirmal Bang’s Diwali portfolio highlights eight stocks poised for durable growth.

Mapping India’s Pharma Supply Chain Amid Shifting Global Currents

… materials, particularly active pharmaceutical ingredients (APIs) … , Executive Vice President, GlaxoSmithKline Pharmaceuticals ; Ajay Bagga, Managing … – Operations, Mankind Pharma ; Sreenivas Rao Nandigam, … Forecasting Failures in Pharma , Medical Device …

GSK re-enters India’s cancer drug market

GlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gynaecological cancers. This move marks a strategic pivot for GSK, aiming to establish a significant oncology presence in India. The company will import these therapies, focusing on access and affordability through tiered pricing and patient assistance programs.

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. Its prescription medicines range across therapeutic areas such as anti-infective, dermatology, gynecology, diabetes, cardiovascular disease and respiratory diseases. The vaccines products include prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others. The company was founded in 1924 and is headquartered in Mumbai, India.

GlaxoSmithkline Pharmaceuticals Ltd

Neutral Sentiment

With festive cheer returning to the markets, Nirmal Bang has unveiled eight Diwali picks for investors seeking steady compounding stories. The top calls cover heavyweight names like ICICI Bank and Tata Consultancy Services to consumer and manufacturing plays such as Varun Beverages, Finolex Industries, and Stove Kraft.Let’s take a look at Nirmal Bang’s Diwali Muhurat stock recommendations:&nbsp;ICICI Bank: Brokerage recommends “Buy” with a target price of ₹1,631. Current price is ₹1,417. The bank maintains best-in-class asset quality (Gross NPA 1.67%, Net NPA 0.41%) and expects RoA/ROE of 2.3%/17% over FY26 - FY27. Strong cost discipline, fee income, and digital transformation initiatives support sustainable growth.Tata Consultancy Services: Brokerage recommends “Buy” with a target price of ₹3,611. Current price is ₹2,971.8. TCS is strengthening its AI capabilities, supply-side restructuring, and data center expansion to capture new-age technology demand. Trading at 19x FY27E earnings, the company is well-positioned for margin sustenance and growth momentum.Varun Beverages:&nbsp;Brokerage recommends “Buy” with a target price of ₹541. Current price is ₹461.5.&nbsp;International operations now contribute 26% of volumes, with strong growth from South Africa, Morocco, Tanzania, DRC, and Zambia. Expansion of snack offerings, backward integration, and distribution network support consistent double-digit growth.Finolex Industries: Brokerage recommends “Buy” with a target price of ₹278. Current price is ₹191.2. The company is set to benefit from both rural and urban demand as it caters to the agriculture and housing sectors.Its ongoing capacity expansion, disciplined pricing, and focus on operational efficiency are expected to enhance margins. ROCE at 27% in FY25 is likely to improve with business revival. Trading at a PE of 27.9x/22.1x on FY26E/FY27E, the stock remains at a discount to peers due to earnings volatility.Diffusion Engineers:&nbsp;Brokerage recommends “Buy” with a target price of ₹466. Current price is ₹380.&nbsp; The company is well-positioned for long-term growth, supported by capacity expansion, strong demand from the cement and steel sectors, and value-added engineering services.With expected improvements in ROCE and EPS, the stock appears reasonably valued at a forward P/E of 24.6x FY27.GSK Pharma: Brokerage recommends “Buy” with a target price of ₹3,425. Current price is ₹2,718.&nbsp; GSK is expected to deliver steady revenue growth of 10% CAGR and profit after tax at 12% CAGR over FY25 - FY27, driven by general medicines, adult vaccination, and specialty launches. The stock trades at 40.6x FY27E EPS, offering a favorable entry point given potential margin expansion.GNG Electronics:&nbsp;Brokerage recommends “Buy” with a target price of ₹482. Current price is ₹328.9. GNG is well-placed to capture ESG-driven and affordability-led IT demand globally. Revenues/EBITDA grew at 46%/59.5% CAGR during FY23-25, the company has strong partnerships across 38 countries, and the stock trades at 20.9x FY27E EPS.Stove Kraft: Brokerage recommends “Buy” with a target price of ₹870. Current price is ₹691.5. Growth drivers include margin expansion, debt reduction, overseas business growth, and favorable consumption trends. Revenue is expected to grow at 13% CAGR and PAT at a 58% CAGR between FY25 and FY27.Disclaimer: The views and opinions expressed are those of the SEBI-registered analyst/advisor mentioned in the article, and are not endorsed by Stocktwits. This is not investment advice. Please do your own research or consult a financial advisor.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Current Price	2,501.00
Prev Close	2,567.90
Open	2,555.10
Dividend Yield	2.50%
50-Day Moving Average	2,802.98
Beta	0.03
Avg. Volume	79,038.52
PE Ratio	39.58

52-Week High	3,120.70
52-Week Low	2,088.10
Market Capitalization	421.77B
EPS (Annual)	61.15
Price to Book	18.64
Revenue Per Employee	12.32M

Feed

News

Sentiment

Fundamentals

Info

GLAXO.NSE Fundamentals